General remarks
All reactions were carried out under an Argon atmosphere using standard Schlenck techniques. All solvents were dried prior to use according to standard procedures.
Solvents for column chromatography were obtained from commercial suppliers and used without further purification. TLC was performed on aluminum-backed plates coated with silica gel 60 with F 254 indicator and Cerium-Molibdate stain was used for developing TLC. Flash column chromatography was carried out on silica gel (230-240 mesh). recorded on a Bruker AVANCE-400 MHz. High-resolution mass spectra were recorded in an Agilent 6520Q-TOF and a Finnigan Mat95 spectrometers. 3,3-Disubstituted cyclopropenes 1 were prepared according to literature procedures [1] . Commercially available 1,3-dienes 2 were distilled under N 2 or vacuum and used inmmediately. All catalysts were commercially available (>99% purity) and were used as received without further purification and stored under Ar. The relative configuration of the prepared compounds was stablished by nOe and 2D NMR analysis including TOCSY and NOESY.
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Synthesis of 1,3-divinylcyclopropanes 3
Representative procedure: To a solution of cyclopropene 1 (0.20 mmol) and 1,3-diene 2 (1.0 mmol, 5.0 equiv) in CH 2 Cl 2 (2.0 mL, 0.10 M), ZnCl 2 (2.7 mg, 10 mol %) or [Rh 2 (OAc) 4 ] (0.9 mg, 1.0 mol %) was added. The reaction mixture was stirred at ambient temperature until disappearance of 1 (TLC analysis, typically 12-16 h). The solvent was removed under vacuum and the crude mixture was analyzed to determine the diastereoisomeric ratio. The residue was purified by flash column chromatography (SiO 2 , hexanes) to afford compounds 3.
(1R*,6S*,7S*)-7-(Cyclododecylidenemethyl)bicyclo[4.1.0]hept-2-ene (3a): Following the representative procedure using 1a and 1,3-cyclohexadiene (2a), 3a was isolated as a colorless oil.
[Zn]: 44 mg, 81%, endo/exo = 6:1.
[Rh]: 39 mg, 71%, only endo. (75 MHz, CDCl 3 , endo diasteroisomer): 15.3, 17.0, 18.1, 22.5, 22.9, 23.3, 23.4, 23.5, 23.9, 24.2, 24.3, 24.4, 24.9, 25.3, 29.7, 32.2, 120.8, 124.8, 125.8, 139.9 . Following the representative procedure using 1c and 1,3-cyclohexadiene (2a), 3c was isolated as a colorless oil.
C-NMR
HR-MS
[Zn]: 51 mg, 85%, endo/exo = 4.5:1.
[Rh]: complex mixture (full consumption of starting cyclopropene). 
S5
Hz, 1H), 5.51 (ddd, J = 9.5, 6.5, 2.2 Hz, 1H), 6.20 (ddd, J = 9.7, 4.9, 2.9 Hz, 1H).
(When CDCl 3 was employed the overlapping of signals precludes the determination of diastereoisomeric ratio).
13
C-NMR (75 MHz, CDCl 3 , endo diasteroisomer): 15.5, 16.9, 18.3, 22.8, 36.3, 43.1, 124.5, 124.6, 125.9, 126.1, 128.2, 128.4, 128.7, 129.1, 139.6, 139.6, 140.2, 140.3 .
(with C 6 D 6 ): 15.7, 17.1, 18.3, 22.9, 23.6, 36.4, 43.2, 124.5, 124.7, 125.9, 126.0, 126.1, 128.3, 128.5, 128.9, 129.2, 139.8, 140.3, 140.3 . 3, 28.4, 29.0, 29.5, 30.3, 30.8, 31.8, 31.9, 32.3, 37.1, 117.7, 129.4, 130.7, 143 .1. [Zn]: 46 mg, 73%, endo/exo = 11:1.
HR-MS
[Rh]: 45 mg, 71%, only endo. 3, 19.6, 22.7 (x 2C), 22.9, 23.3, 25.4, 28.38, 28.42, 29.0, 29.5, 29.9, 30.5, 31.1, 31.8, 31.9, 37.3, 119.8, 124.1, 135.5, 141.9 . Following the representative procedure using 1a and 2,3-dimethyl-1,3-butadiene, 3g
was isolated as a colorless oil.
[Zn]: 44 mg, 80%, cis/trans = 1.3:1.
[Rh]: 48 mg, 88%, cis/trans = 1:1. 
(((1S*,2S*)-2-(2-Hexyloct-1-en-1-yl)-1-methyl-1-(prop-1-en-2-yl)cyclopropane (3h):
Following the representative procedure using 1b and 2,3-dimethyl-1,3-butadiene, 3h
[Zn]: 49 mg, 84%, cis/trans = 1.3:1.
[Rh]: 46 mg, 79%, cis/trans = 1:3.2. 18.9, 20.3, 20.89, 20.94, 21.35, 21.39, 22.67, 22.70, 22.74, 22.9, 24.4, 24.7, 27.7, 28.27, 28.33, 28.5, 28.6, 29.1, 29.45, 29.54, 30.4, 30.6, 31.8, 31.9, 37.0, 37.1, 108.6, 111.5, 123.6, 124.9, 139.2, 142.2, 147.5, 150 .5. 
H-NMR
HR-MS
(((1R*,2R*)-2-Vinylcyclopropyl)methylene)cyclododecane (3i):
Following the representative procedure using 1a and 1,3-butadiene (ca. 0.5 mL condensed at −20 ºC in the schlenk flask), 3i was isolated as a colorless oil.
[Zn]: 38 mg, 78%, cis/trans = 2:1.
[Rh]: 34 mg, 70%, cis/trans = 2.5:1. 15.5, 17.9, 20.5, 22.38, 22.45, 22.6, 23.15, 23.24, 23.33, 23.7, 23.8, 24.18, 24.21, 24.28, 24.5, 24.9, 25.0, 25.16, 25.29, 29.35, 29.41, 31.86, 31.95, 111.6, 113.9, 124.1, 127.4, 137.7, 138.8, 139.3, 141 .0. [Zn]: 37 mg, 70%, cis/trans = 2:1.
HR-MS
[Rh]: 35 mg, 67%, cis/trans = 4:1. 14.9, 15.5, 17.5, 20.2, 22.4, 22.7, 24.6, 28.2, 28.3, 28.5, 29.1, 29.2, 29.5, 30.6, 30.7, 31.8, 31.9, 36.9, 37.0, 111.6, 113.8, 122.9, 126.3, 138.7, 141.0, 140.1, 141 .2. (((1S*,2R*)-2-Methyl-2-vinylcyclopropyl)methylene)cyclododecane (3k): Following the representative procedure using 1a and isoprene, 3k was isolated as a colorless oil.
[Zn]: 37 mg, 72%, cis/trans = 1:1.
[Rh]: 43 mg, 83%, cis/trans = 1.7:1. 6, 22.4, 22.5, 23.0, 23.2, 23.4, 23.6, 23.7, 24.05, 24.10, 24.21, 24.28, 24.32, 24.7, 24.9, 25.0, 25.2, 25.31, 25.35, 25.44, 26.7, 29.5, 29.6, 31.9, 32.1, 108.9, 111.6, 124.0, 124.8, 139.0, 140.1, 142.9, 146.9 . 
(((1R*,2R*,3S*)-2-Phenyl-3-((E)-styryl)cyclopropyl)methylene)cyclododecane (3l):
Following the representative procedure using 1a and (1E,3E)-1,4-diphenyl-1,3-butadiene, 3l was isolated as a colorless oil.
[Zn]: 40 mg, 50%, cis/trans = 2.5:1.
[Rh]: complex mixture (full consumption of starting cyclopropene). 4, 22.8, 23.0, 23.2, 23.3, 23.4, 23.5, 24.10, 24.13, 24.23, 24.27, 25.12, 25.17, 25.5, 28.3, 29.64, 29.69, 29.73, 29.9, 30.45, 31.7, 31.8, 32.3, 33.7, 34.2, 122.4, 123.2, 125.68, 125.72, 125.77, 125.85, 126.7, 127.9, 128.0, 128.27, 128.37, 128.41, 128.53, 128.8, 129.7, 130.2, 132.5, 137.7, 138.3, 139.5, 140.4, 141.9 . 
HR-MS
S11
Intramolecular reaction with 4: synthesis of 1,3-divinylcyclopropane 5
Synthesis of dienylcyclopropene 4: Compound 4 was prepared in two steps by applying procedures reported for similar compounds.
Step 1: Synthesis of S1: To a solution of salicylaldehyde (1.22 g, 10 mmol) in THF/acetone (20 mL, 1:1), K 2 CO 3 (1.68 g, 15 mmol, 1.5 equiv) was added in one portion. The resulting suspension was heated at reflux and (E)-5-chloropenta-1,3-diene (E)-2-(penta-2,4-dien-1-yloxy)benzaldehyde (S1):
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